KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) Revenue: 2017-2025

Historic Revenue for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Sep 2025 value amounting to $784.5 million.

  • Amneal Pharmaceuticals' Revenue rose 11.68% to $784.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 billion, marking a year-over-year increase of 9.50%. This contributed to the annual value of $2.8 billion for FY2024, which is 16.73% up from last year.
  • Latest data reveals that Amneal Pharmaceuticals reported Revenue of $784.5 million as of Q3 2025, which was up 8.28% from $724.5 million recorded in Q2 2025.
  • Amneal Pharmaceuticals' Revenue's 5-year high stood at $784.5 million during Q3 2025, with a 5-year trough of $493.1 million in Q1 2021.
  • Over the past 3 years, Amneal Pharmaceuticals' median Revenue value was $695.4 million (recorded in 2025), while the average stood at $672.0 million.
  • Its Revenue has fluctuated over the past 5 years, first declined by 1.09% in 2021, then rose by 18.40% in 2024.
  • Over the past 5 years, Amneal Pharmaceuticals' Revenue (Quarterly) stood at $536.9 million in 2021, then rose by 13.57% to $609.8 million in 2022, then increased by 1.18% to $617.0 million in 2023, then grew by 18.40% to $730.5 million in 2024, then increased by 11.68% to $784.5 million in 2025.
  • Its Revenue was $784.5 million in Q3 2025, compared to $724.5 million in Q2 2025 and $695.4 million in Q1 2025.